Inactive Instrument

Varian Medical Systems, Inc.

Equities

VAR

US92220P1057

Tranche Update on Varian Medical Systems, Inc.'s Equity Buyback Plan announced on November 21, 2016.

January 23, 2019 at 04:20 pm

From September 29, 2018 to December 28, 2018, the company has repurchased 320,000 shares, representing 0.35% for $34.85 million. With this, the company has completed the repurchase of 4,720,000 shares, representing 5.11% for $465.24 million under the buyback announced on November 21, 2016.

Latest news about Varian Medical Systems, Inc.

Varian Announces Exclusive US Distribution Agreement with Innova Vascular for New Innovative Thrombectomy Solutions	05-15	CI
Varian Showcases Commitment to Embracing Innovation and Enhancing Outcomes At ESTRO 2024	05-02	CI
Varian Collaborates with BaraSeen Medical Company to Pave the Way for Advanced Cancer Treatment in Saudi Arabia with Sustainable Halcyon Technology	04-25	CI
Varian and Nova Scotia Health Form First Multi-Disciplinary Oncology Partnership to Catalyze Advancements in Cancer Care	01-04	CI
Varian Medical Systems, Inc. acquired Aspekt Solutions.	23-09-25	CI
Varian Announces First Participant Treated in RADIATE-VT Clinical Trial of Cardiac Radioablation for Patients with Refractory Ventricular Tachycardia	23-05-19	CI
Varian Collaborating with Nova Scotia Health to Transform Cancer Care	23-02-17	CI
Varian Receives Investigational Device Exemption for Flash Technology Clinical Trial, FAST-02	22-06-27	CI
Adaptiiv Collaborates with HP and Varian to Enhance Personalization in Radiation Oncology with 3D Printed Medical Devices	22-05-06	CI
Oulu University Hospital in Finland Enters Long-Term Strategic Partnership with Varian and Siemens Healthineers	22-01-19	CI
Varian and Icon Oncology Partner to Establish Value-Based Cancer Treatment Hub for Southern Africa	21-12-14	CI
Varian and the Cincinnati Children's/UC Health Proton Therapy Center Complete Enrollment of FAST-01, First Human Clinical Trial of FLASH Therapy for Cancer	21-10-25	CI
Varian Medical Systems, Inc. Receives FDA "Breakthrough Device Designation" For Embozene® Microspheres For Genicular Artery Embolization For Symptomatic Knee Osteoarthritis	21-10-13	CI
Elekta : Medical equipment maker Elekta sees higher supply chain costs, shares fall	21-08-25	RE
Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian	21-08-05	CI
Siemens : Targets Higher Full-Year Profit As Demand Surge Beats Supply Chain Woes	21-08-05	MT
Siemens Backs Fiscal Year 2021 Outlook, Including Varian Deal	21-06-24	DJ
Varian Receives FDA "Breakthrough Device Designation" for its Cardiac Radioablation System for Treatment of Refractory Ventricular Tachycardia (VT)	21-05-26	CI
Siemens : Raises FY21 Outlook As Fiscal H1 Profit Doubles	21-05-07	MT
Siemens Healthineers : Strong COVID-19 Antigen Test Sales Prompt Siemens Healthineers Full-Year Guidance Boost	21-05-03	MT
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 EQUAL WEIGHTED	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P TMI Index	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P Global BMI Index	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500	21-04-20	CI
Varian Medical Systems, Inc.(NYSE:VAR) dropped from S&P 500 Growth	21-04-20	CI

Chart Varian Medical Systems, Inc.

Duration

Period

More charts

Company Profile

Varian Medical Systems, Inc. is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, cardiac radioablation, radiosurgery, proton therapy and brachytherapy. The Company also has Varian Particle Therapy (VPT) and the operations of the Ginzton Technology Center (GTC). Its VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, another form of external beam radiotherapy using proton beams for the treatment of cancer. Its ProBeam system is capable of delivering intensity modulated proton therapy (IMPT) using pencil beam scanning technology. Its ProBeam Compact is a single room proton therapy product. Through its subsidiary, Cooperative CL Enterprises, the Company distributes radiotherapy equipments in Taiwan.

Sector

More about the company